NCT03747328View on ClinicalTrials.gov

ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
Leigh Syndrome
Interventions
DRUG

ABI-009

nanoparticle albumin bound sirolimus

Sponsors
All Listed Sponsors
lead

Aadi Bioscience, Inc.

INDUSTRY